Skip to main content
. Author manuscript; available in PMC: 2019 Feb 4.
Published in final edited form as: Expert Rev Anticancer Ther. 2010 Jul;10(7):997–1008. doi: 10.1586/era.10.88

Figure 5. Patient with cutaneous T-cell lymphoma who presented with extensive erythematous skin nodules.

Figure 5.

Prior therapy had included Psoralen + UVA, deoxycoformycin, Doxil®, and denileukin diftitox. Complete response noted after 7 months on romidepsin, maintained another 18 months. Developed minimal patch disease, and no therapy was required for an additional 4 years after discontinuation of romidepsin.